Prelude therapeutics incorporatedPRLD.US Overview
PRLD Overall Performance
PRLD AI Analysis & Strategy
PRLD Recent Performance
-1.50%
Prelude therapeutics incorporated
0.81%
Avg of Sector
-1.14%
S&P500
PRLD PowerScanner
PRLD Key Information
PRLD Valuation Metrics
PRLD Earnings Table
PRLD Profile
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.